购物车
- 全部删除
- 您的购物车当前为空
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections.
为众多的药物研发团队赋能,
让新药发现更简单!
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 1,370 | 5日内发货 | |
5 mg | ¥ 2,760 | 5日内发货 | |
25 mg | ¥ 9,620 | 8-10周 | |
50 mg | ¥ 12,500 | 8-10周 | |
100 mg | ¥ 19,300 | 8-10周 |
产品描述 | Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections. |
体外活性 | Avarofloxacin demonstrates an antibacterial effect against numerous Gram-positive bacteria (mean MIC90: 0.12 mg/L) [2]. Avarofloxacin has the potential for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections [3]. |
别名 | JNJ-Q2 |
分子量 | 419.42 |
分子式 | C21H23F2N3O4 |
CAS No. | 878592-87-1 |
密度 | 1.450 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容